1. Introduction

Biotech sanctions compliance is the system of legal controls, internal policies, screening procedures and monitoring mechanisms that biotechnology companies use to ensure their activities do not violate economic sanctions, trade restrictions, export controls or prohibitions involving biological materials and technologies.

The subject is particularly important for biotechnology companies engaged in pharmaceuticals, vaccines, genetic engineering, genomic sequencing, synthetic biology, laboratory equipment, clinical trials, contract research, biological sample transfers and international scientific collaboration.

Sanctions may restrict dealings with designated persons, companies, financial institutions, governments, territories or particular sectors. Export-control rules may separately restrict the transfer of sensitive biological materials, equipment, software, technical information and research capabilities.

A critical distinction is that sanctions compliance and export-control compliance are related but legally separate obligations. A transaction may be permitted under sanctions rules yet require an export licence, or it may involve ordinary laboratory materials but still be prohibited because of the recipient, ownership structure, destination or end use.

This explanation focuses on the principal international frameworks and relevant judicial decisions, particularly those from the United States, the European Union and the United Kingdom, with reference to India where relevant. The precise legal position depends on the jurisdiction, transaction date, parties and technology involved.

2. Objectives of biotech sanctions compliance

The principal objectives are:

Prevent prohibited transactions: Avoid supplying biotechnology products, services, funding or technical assistance to sanctioned persons or entities.

Protect sensitive technologies: Prevent unauthorised transfers of dual-use biological equipment, pathogens, genetic engineering capabilities and technical know-how.

Ensure lawful humanitarian access: Distinguish prohibited commercial activity from authorised medical, pharmaceutical and humanitarian transactions.

Protect research integrity: Ensure that universities, laboratories, contract research organisations and research sponsors comply with applicable restrictions.

Maintain financial compliance: Prevent prohibited payments, investments, insurance arrangements and transfers through intermediaries.

Reduce enforcement risk: Avoid civil penalties, criminal liability, licence revocation, asset freezes and reputational damage.

Biotechnology presents special challenges because the same technology can have beneficial medical applications and potentially harmful uses. A genomic analysis platform, fermentation system or laboratory instrument may support ordinary healthcare research but could also be subject to controls because of its technical capabilities or intended use.

3. Principal legal frameworks

A. United States — OFAC sanctions and export controls

The Office of Foreign Assets Control (OFAC) administers US economic sanctions. Relevant rules may prohibit dealings with designated persons, restrict transactions involving certain jurisdictions, and limit the provision of services or financing.

The Export Administration Regulations (EAR), administered by the Bureau of Industry and Security, may independently control biological materials, laboratory equipment, software and technology. The International Traffic in Arms Regulations may apply to certain defence-related biological or technical items.

US persons are generally subject to applicable OFAC sanctions worldwide. Certain foreign persons and transactions can also be covered by specific rules, including prohibitions on evasion and unauthorised re-exports.

Office of Foreign Assets Control

B. European Union — restrictive measures and dual-use controls

EU sanctions regulations can freeze assets, prohibit making funds or economic resources available to listed persons, and restrict specified goods, technologies, technical assistance or services.

Regulation (EU) 2021/821 establishes the EU dual-use export-control framework. Relevant controls depend on the item, destination, end user, end use and applicable authorisation or catch-all provisions.

A biotech business must examine both the applicable sanctions regulation and the dual-use classification of its products.

C. United Kingdom — sanctions and strategic export controls

The Sanctions and Anti-Money Laundering Act 2018 provides the principal framework for UK sanctions regulations. Depending on the transaction, prohibitions may concern funds, economic resources, trade, technical assistance or services.

The Export Control Order 2008 and relevant retained or assimilated dual-use rules, as applicable, may also regulate controlled technology and goods. UK persons and businesses must assess the territorial and personal scope of each applicable rule.

GOV.UK

D. India — SCOMET and strategic trade controls

India regulates specified dual-use items through the SCOMET (Special Chemicals, Organisms, Materials, Equipment and Technologies) framework under the Foreign Trade Policy and the Foreign Trade (Development and Regulation) Act 1992.

Category 2 is particularly relevant to specified microorganisms and toxins. Other categories may cover associated equipment, materials or technology. Listing, technical specifications, exemptions and authorisation requirements must be checked against the current SCOMET list.

India's framework also addresses unauthorised technical assistance, transfers and potential diversion of items to weapons-of-mass-destruction activities.

Mumbai Customs Zone – III+2

4. What activities can create sanctions risk?

Important: A product's medical purpose does not automatically exempt the transaction from sanctions or export controls. Conversely, a restriction on a particular product or recipient does not necessarily prohibit all medical research or humanitarian supply in the relevant country. The exact rule, exemption and licensing mechanism must be examined.

5. Essential elements of a compliance programme

5.1 Sanctions screening

A biotechnology business should screen, as appropriate:

Customers, distributors, suppliers and contract research organisations.

Beneficial owners, parent companies and entities under relevant ownership or control rules.

Banks, insurers, freight forwarders and other transaction intermediaries.

Research collaborators, institutional sponsors and recipients of technical assistance.

Screening should take place at onboarding and again before relevant transactions, with periodic rescreening and controls for changes in sanctions lists.

A simple name match should not automatically be treated as a confirmed violation. Compliance personnel should verify identities, ownership, location and relevant listing details, then document the decision.

5.2 Product and technology classification

The company should determine whether each relevant product, organism, toxin, instrument, software package or technical dataset is controlled.

This requires examining technical specifications, not merely commercial product names. For example, a laboratory instrument may have a different classification depending on its capabilities, accompanying software or technical documentation.

5.3 End-user and end-use verification

Companies should assess whether a proposed recipient is authorised to receive the product and whether the declared use is credible.

Potential warning signs include:

A customer refusing to identify the final recipient.

Orders inconsistent with the customer's business or laboratory capabilities.

Unexplained routing through third countries.

Requests to conceal the recipient or alter product descriptions.

Links to prohibited weapons programmes or sanctioned organisations.

A warning sign is not proof of wrongdoing, but it can justify enhanced due diligence, a hold on shipment or escalation to legal counsel.

5.4 Licensing and exemptions

Where a transaction may be restricted, the company should identify the relevant licence, permit, general authorisation or statutory exception before proceeding.

Medical and humanitarian exceptions must be read carefully. They may cover particular goods or activities while leaving payment processing, technical assistance, counterparties or other parts of the transaction restricted.

The European Commission publishes specific guidance on providing humanitarian aid in environments subject to EU restrictive measures.

Finance+1

5.5 Recordkeeping and internal governance

A defensible programme should retain:

Screening results and the date of each check.

Product classifications and supporting technical assessments.

End-user certificates and destination information.

Licences, permits and exemption analyses.

Approval records, payment documentation and shipping records.

Investigations, escalation decisions, corrective actions and training records.

Records should be kept for the period required by the applicable law and any relevant licence conditions.

6. Important case laws and judicial principles

There is no single universal body of case law specifically governing sanctions compliance in biotechnology. The following decisions establish broader legal principles that are relevant to biotech businesses dealing with restricted counterparties, controlled technologies and cross-border transactions.

Case 1: Bank Melli Iran v. Telekom Deutschland GmbH (2021)

Court of Justice of the European Union · Case C-124/20 · Judgment of 21 December 2021

Facts: The dispute concerned a German telecommunications company that terminated its contracts with an Iranian bank subject to US sanctions. The case examined the EU Blocking Statute, Regulation (EC) No 2271/96, which restricts compliance with certain listed extraterritorial foreign laws.

Legal issue: Could a European company terminate a contractual relationship because of US sanctions without infringing the EU Blocking Statute?

Decision: The Court interpreted the Blocking Statute as applying even where a company had not received a specific order from a US authority. It also explained that national courts must consider whether a termination infringes the statute and assess proportionality in light of the circumstances.

Cour de justice de l’Union européenne+1

Relevance to biotechnology: A European pharmaceutical company cannot assume that following US sanctions automatically satisfies its EU obligations. Terminating a research, supply or distribution contract involving an Iranian counterparty may require a separate assessment of EU law.

Case 2: The Queen, on the application of Rosneft Oil Company v. Her Majesty's Treasury (2017)

Court of Justice of the European Union · Case C-72/15 · Judgment of 28 March 2017

Facts: Rosneft challenged restrictive measures imposed by the EU in response to Russia's actions concerning Ukraine. The measures included restrictions on certain financial transactions and sensitive goods and technologies.

Legal issue: Whether the relevant restrictive measures were valid and whether the EU courts could review aspects of their legality.

Decision: The Court confirmed its jurisdiction to give preliminary rulings on the validity of relevant restrictive measures adopted under the EU's Common Foreign and Security Policy. It upheld the challenged measures.

curia+1

Relevance to biotechnology: A biotech business should evaluate sectoral sanctions and technology restrictions independently of whether a customer appears on an individual sanctions list. Restrictions on specified goods, financing or services can apply to transactions with entities that are not themselves individually designated.

Case 3: Youssef v. Secretary of State for Foreign and Commonwealth Affairs (2016)

UK Supreme Court · [2016] UKSC 3 · Judgment of 27 January 2016

Legal significance: This case concerned the consequences of international counterterrorism sanctions and the judicial treatment of allegations underlying restrictive measures.

It is relevant to the broader principles of evidence, procedural fairness and review of decisions affecting individuals through sanctions mechanisms.

UK Supreme Court

Relevance to biotechnology: A company should maintain reliable evidence supporting its screening decisions, distinguish verified matches from uncertain matches and establish a process for resolving mistaken identity or contested designation issues.

This case should not be read as establishing a biotechnology-specific compliance defence.

Case 4: Afrasiabi and Others (2011)

Court of Justice of the European Union · Case C-72/11 · Judgment of 21 December 2011

Legal significance: This Iranian sanctions case addressed the interpretation of prohibitions concerning the making available of economic resources to facilitate prohibited activities. The Court examined the scope of the relevant restrictive measures and the legal significance of indirect assistance.

Relevance to biotechnology: Businesses must look beyond the immediate buyer. Supplying equipment, financing or technical support through an intermediary may create sanctions exposure if the arrangement falls within a prohibition on indirect provision or facilitation. The exact legal elements depend on the applicable sanctions regulation. The judgment can be located through the EU Court's case-law database.

Documents+1

Comparative case-law summary

These cases are relevant by analogy and do not replace the wording of the specific sanctions or export-control provisions governing a transaction.

7. Humanitarian and medical exceptions

Medical research and healthcare activities may benefit from exemptions, derogations or licensing mechanisms, but the scope varies by jurisdiction and sanctions programme.

Examples include:

Supplying eligible medicines and medical devices.

Conducting authorised clinical research.

Providing humanitarian assistance through approved organisations.

Making payments permitted under a specific licence.

Sharing information or technical assistance where expressly authorised.

The compliance team should verify the entire transaction, including the recipient, bank, freight provider, technical services and any associated financing. An exemption for a medicine does not necessarily authorise every service or payment associated with it.

The EU and Australian authorities publish guidance addressing humanitarian operations and the risk of prohibited resources reaching designated entities.

Finance+2

8. Enforcement, penalties and corporate liability

Sanctions violations can result in different consequences depending on the jurisdiction and the nature of the conduct.

Civil and administrative penalties

Financial penalties, settlement payments, loss of authorisations and restrictions on future transactions.

Criminal consequences

Where the relevant law's requirements are satisfied, intentional evasion, prohibited exports, conspiracy or other offences may lead to prosecution and imprisonment.

Commercial consequences

Contract termination, frozen payments, loss of banking access, disrupted clinical trials, exclusion from supply chains and reputational harm.

Under US law, OFAC enforcement can involve civil and, in some cases, criminal penalties. The applicable penalty depends on the governing programme, conduct and enforcement provisions.

Office of Foreign Assets Control

In India, unauthorised exports of controlled SCOMET items and other export-control violations can trigger consequences under the applicable legislation and authorisation conditions. DGFT's voluntary-disclosure guidance states that qualifying disclosures may be considered as a mitigating factor in administrative penalty decisions; it is not a blanket immunity from enforcement.

DGFT Content

9. Practical compliance example

Consider an Indian biotechnology company planning to export specialised laboratory materials to a foreign research institution.

A sound compliance process would proceed as follows:

Identify the product. Determine its technical characteristics and whether it falls within the current SCOMET list or another applicable control regime.

Screen the parties. Check the institution, its ownership, relevant researchers, intermediaries and payment banks against applicable sanctions restrictions.

Verify end use. Obtain credible information about the intended research and the final destination.

Determine authorisation requirements. Identify required export licences, permits and any applicable exceptions before shipment or transfer.

Resolve warning signs. Pause the transaction if ownership, end use or destination cannot be adequately verified.

Document and monitor. Preserve the assessment and licences, monitor changes to the transaction, and investigate any suspected diversion.

If the institution is not listed but the product is controlled, an export authorisation may still be necessary. Conversely, if the product is not controlled, a sanctions prohibition may nevertheless apply because of the recipient, financing or transaction structure.

For current Indian requirements, consult the Ministry of External Affairs' SCOMET and strategic trade controls resources and the relevant DGFT notifications.

Ministry of External Affairs+1

10. Conclusion

Biotech sanctions compliance requires an integrated assessment of the product, the recipient, the destination, the end use, the payment structure and the governing jurisdiction. A company should not rely exclusively on sanctions-list screening or assume that medical and scientific activities are automatically exempt.

The case law demonstrates three especially important principles:

Different jurisdictions can impose conflicting legal obligations.

Restrictions can cover particular sectors, technologies and indirect transactions, not just listed persons.

Compliance decisions should be supported by evidence, proper legal analysis and documented procedures.

The strongest compliance programme combines screening, technical classification, end-use checks, licensing, employee training, recordkeeping and a clear escalation process.

Legal note: This is a general educational overview, not legal advice. The precise result depends on the applicable legislation, current sanctions designations, transaction facts and relevant judicial authority.

Suggested next step: A useful continuation would be a jurisdiction-specific analysis of Biotech Sanctions Compliance in Australia, including the Autonomous Sanctions Act 2011, export controls, relevant case law and a practical corporate compliance checklist.